Abstract | BACKGROUND: This study assessed safety and efficacy for intratumoral administration of tumor necrosis factor-a (TNF-SAM2) into the post-operative tumor cavity through an Ommaya reservoir for patients with malignant glioma. MATERIALS AND METHODS: RESULTS: Partial response to this regional immunotherapy was seen in 4 out of 7 patients, and 1 patient with GBM has remained clinically stable for >184 weeks without tumor progression. With AA, 2 cases appeared to display slowed advance and longer times to tumor recurrence or regrowth. No serious adverse effects, such as brain edema, hemorrhage or seizure were observed, nor systemic toxicities. CONCLUSION:
|
Authors | Shinya Oshiro, Hitoshi Tsugu, Fuminari Komatsu, Hirokazu Ohnishi, Yushi Ueno, Seizaburo Sakamoto, Takeo Fukushima, Gen-Ichiro Soma |
Journal | Anticancer research
(Anticancer Res)
2006 Nov-Dec
Vol. 26
Issue 6A
Pg. 4027-32
ISSN: 0250-7005 [Print] Greece |
PMID | 17195453
(Publication Type: Case Reports, Clinical Trial, Journal Article)
|
Chemical References |
- TNF-SAM2
- Tumor Necrosis Factor-alpha
|
Topics |
- Adult
- Aged
- Female
- Glioma
(immunology, therapy)
- Humans
- Injections, Intralesional
- Male
- Middle Aged
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(administration & dosage, adverse effects)
|